Opinion Archives - IPHA
November 4, 2022

Policymakers should heed the shifting landscape for medicines innovation, writes Bernard Mallee

The biopharmaceutical industry is surging. But believing that the surge is permanent, or inevitable, would be a mistake. Like other industries, we are buffeted by international […]
June 20, 2022

Adopting Innovation

Sustained funding and an agile reimbursement system can improve care standards, writes Jim McGrath   The reason medicines are reimbursed is that they improve the standard […]
June 20, 2022

Give patients faster access to new medicines, writes Bernard Mallee

Irish patients deserve faster access to the best new medicines. We are slower than almost every other western European country to give the latest medicines to […]
June 19, 2022

Europe faces choice between innovation or the risk of stagnation, writes Bernard Mallee

A quarter of a century ago, almost half of global new treatments originated in Europe. Today, the proportion has dropped to 22%. The United States has […]
January 20, 2022

Better health and economic prospects depend on the right policy environment, writes Bernard Mallee

Recent figures showing buoyant tax revenues demonstrate the resilience of the economy during the pandemic. As some of the domestic sector struggles, the economy’s overall performance […]
May 31, 2021

We need a policy for making ‘breakthrough’ cell and gene therapies available to patients, writes Bernard Mallee

As if Covid-19 wasn’t enough, the health service was hit by a ransomware attack, delaying care for patients across the country. Hackers exposed the vulnerabilities of […]
March 29, 2021

How much value do innovative medicines generate for the economy?

How much value do innovative medicines generate for the economy? by Bernard Mallee More than a year since the World Health Organisation declared Covid-19 a pandemic, […]
January 11, 2021

Adequate funding, not a dilution of IP rights, will tackle delays in adopting new medicines, says IPHA submission to European Commission

Access to new treatments can be improved by sustainable, predictable Government budgeting, not by weakening intellectual property (IP) rights for medicines development, according to a submission […]
January 11, 2021

Astellas tells a story of rural innovation as part of ‘Innovate For Life’

The Astellas plant in Killorglin, Co Kerry, is among the companies that feature in ‘Innovate For Life’ – the IPHA campaign that gives a platform to […]